2017 American Society of Hematology Annual Meeting*

Download All
December 9-12, 2017; Atlanta, Georgia
Review expert perspectives on key findings on novel targeted therapies in hematologic malignancies presented at the 2017 ASH annual meeting.
Farrukh Awan, MD, MS
Daniel J. DeAngelo, MD, PhD
Madeleine Duvic, MD
Marie Anne Scully, MD

Novel Targeted Therapies in Hematologic Malignancies

At a median follow-up of 33.9 months, brentuximab vedotin showed superior outcomes and durable responses vs either methotrexate or bexarotene for patients with previously treated, CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma.

Released: December 20, 2017

Avapritinib was well tolerated and safe across several dose levels with an ORR of 72% by IWG-MRT-ECNM criteria.

Released: December 20, 2017

Novel chemotherapy-free combination of avadomide plus obinutuzumab tolerable and active in patients with relapsed/refractory NHL.

Released: December 12, 2017

The combination of acalabrutinib and obinutuzumab yielded ORR rates exceeding 90% that deepened over time, along with a favorable safety profile.

Released: December 15, 2017

Mogamulizumab approximately doubled median PFS compared with vorinostat in patients with previously treated CTCL.

Released: December 19, 2017

In this expert analysis of key data from the Hematology 2017 annual meeting, the clinical implications of new targeted therapeutic strategies in multiple hematologic diseases (NHL, CLL, CTCL, systemic mastocytosis, and acquired TTP) are reviewed by Farrukh Awan, MD, MS; Madeleine Duvic, MD; Daniel J. DeAngelo, MD, PhD; and Marie Ann Scully, MD.

Farrukh Awan, MD, MS Daniel J. DeAngelo, MD, PhD Madeleine Duvic, MD Marie Anne Scully, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: February 16, 2018 Expired: No longer available for credit

Composite of aTTP-related death, aTTP recurrence, and major thromboembolic events significantly reduced with caplacizumab vs placebo.

Released: December 19, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Celgene Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics Inc.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings